Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG015
MIFTS: 47

Lingual-Facial-Buccal Dyskinesia

Categories: Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lingual-Facial-Buccal Dyskinesia

About this section

MalaCards integrated aliases for Lingual-Facial-Buccal Dyskinesia:

Name: Lingual-Facial-Buccal Dyskinesia 12 15 71
Orofacial Dyskinesia 29 6
Oro-Facial Dyskinesia 12
Dyskinesias 43

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:9854
ICD9CM 34 333.82
MeSH 43 D020820
SNOMED-CT 67 49386006
ICD10 32 G24.4
UMLS 71 C0152115
Sources

Summaries for Lingual-Facial-Buccal Dyskinesia

About this section
MalaCards based summary : Lingual-Facial-Buccal Dyskinesia, also known as orofacial dyskinesia, is related to tardive dyskinesia and schizoaffective disorder, and has symptoms including spasmodic torticollis An important gene associated with Lingual-Facial-Buccal Dyskinesia is CSTB (Cystatin B), and among its related pathways/superpathways are Peptide ligand-binding receptors and Beta-Adrenergic Signaling. The drugs Zonisamide and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and subthalamic nucleus, and related phenotypes are behavior/neurological and muscle

Sources

Related Diseases for Lingual-Facial-Buccal Dyskinesia

About this section

Diseases related to Lingual-Facial-Buccal Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 796)
# Related Disease Score Top Affiliating Genes
1 tardive dyskinesia 33.2 DRD3 DRD2
2 schizoaffective disorder 30.9 DRD4 DRD3 DRD2
3 early-onset schizophrenia 30.4 DRD2 DRD1
4 huntington disease 30.2 XK VPS13A GRIN1 DRD2 DRD1
5 choreoacanthocytosis 30.2 XK VPS13A KEL
6 tic disorder 30.1 DRD5 DRD4 DRD3 DRD2 DRD1
7 parkinson disease, late-onset 30.1 HTR2C DRD5 DRD4 DRD3 DRD2 DRD1
8 mental depression 30.0 HTR2C DRD4 DRD2 DRD1
9 schizotypal personality disorder 30.0 DRD4 DRD2
10 alcohol use disorder 30.0 HTR2C DRD3 DRD2 DRD1
11 personality disorder 29.9 HTR2C DRD4 DRD3 DRD2
12 gilles de la tourette syndrome 29.9 DRD5 DRD4 DRD3 DRD2 DRD1
13 cocaine abuse 29.9 DRD3 DRD2 DRD1
14 hemidystonia 29.8 LGI1 JRK
15 benign epilepsy with centrotemporal spikes 29.8 LGI1 GRIN1 CSTB
16 cannabis abuse 29.8 DRD4 DRD2
17 anxiety 29.8 HTR2C DRD4 DRD3 DRD2
18 avoidant personality disorder 29.8 DRD4 DRD3 DRD2
19 blepharospasm 29.7 OMD JRK DRD5
20 focal hand dystonia 29.6 JRK DRD2
21 major depressive disorder 29.6 HTR2C DRD4 DRD3 DRD2 DRD1
22 gastroparesis 29.6 DRD5 DRD4 DRD3 DRD2 DRD1
23 substance abuse 29.6 DRD5 DRD4 DRD3 DRD2 DRD1
24 drug dependence 29.6 DRD3 DRD2 DRD1
25 obsessive-compulsive disorder 29.6 HTR2C DRD4 DRD3 DRD2 DRD1
26 eating disorder 29.5 HTR2C DRD3 DRD2
27 hyperprolactinemia 29.5 HTR2C DRD4 DRD2
28 impulse control disorder 29.5 DRD5 DRD4 DRD3 DRD2 DRD1
29 migraine with or without aura 1 29.5 HTR2C DRD5 DRD4 DRD3 DRD2 DRD1
30 schizophreniform disorder 29.5 DRD5 DRD4 DRD3 DRD2 DRD1
31 dystonia 29.4 XK VPS13A DRD5 DRD3 DRD2 DRD1
32 mood disorder 29.4 XK HTR2C GRIN1 DRD4 DRD3 DRD2
33 cervical dystonia 29.4 OMD JRK DRD5
34 withdrawal disorder 29.4 DRD2 DRD1
35 neurodegeneration with brain iron accumulation 1 29.3 XK VPS13A
36 restless legs syndrome 29.3 DRD5 DRD4 DRD3 DRD2 DRD1
37 bipolar i disorder 29.3 HTR2C DRD4 DRD3 DRD2 DRD1
38 epilepsy, myoclonic juvenile 29.2 LGI1 JRK CSTB
39 migraine without aura 29.2 DRD5 DRD4 DRD3 DRD2 DRD1
40 bipolar disorder 29.2 HTR2C GRIN1 DRD5 DRD4 DRD3 DRD2
41 psychotic disorder 29.2 HTR2C DRD5 DRD4 DRD3 DRD2 DRD1
42 focal dystonia 29.1 OMD JRK DRD5 DRD2
43 pathological gambling 29.0 DRD5 DRD4 DRD3 DRD2 DRD1
44 disease of mental health 29.0 HTR2C DRD5 DRD4 DRD3 DRD2 DRD1
45 tobacco addiction 29.0 DRD5 DRD4 DRD3 DRD2 DRD1
46 pervasive developmental disorder 28.9 DRD5 DRD4 DRD3 DRD2 DRD1
47 autism spectrum disorder 28.9 HTR2C DRD5 DRD4 DRD3 DRD2 DRD1
48 alcohol dependence 28.6 HTR2C GRIN1 DRD5 DRD4 DRD3 DRD2
49 delusional disorder 28.6 HTR2C DRD5 DRD4 DRD3 DRD2 DRD1
50 autism 28.5 HTR2C GRIN1 DRD5 DRD4 DRD3 DRD2

Graphical network of the top 20 diseases related to Lingual-Facial-Buccal Dyskinesia:



Diseases related to Lingual-Facial-Buccal Dyskinesia
Sources

Symptoms & Phenotypes for Lingual-Facial-Buccal Dyskinesia

About this section

UMLS symptoms related to Lingual-Facial-Buccal Dyskinesia:


spasmodic torticollis

MGI Mouse Phenotypes related to Lingual-Facial-Buccal Dyskinesia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 CSTB DRD1 DRD2 DRD3 DRD4 DRD5
2 muscle MP:0005369 9.5 CSTB DRD1 DRD2 FGF14 HTR2C KEL
3 nervous system MP:0003631 9.44 CSTB DRD1 DRD2 DRD3 DRD4 DRD5
Sources

Drugs & Therapeutics for Lingual-Facial-Buccal Dyskinesia

About this section

Drugs for Lingual-Facial-Buccal Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Levetiracetam Approved Phase 4 102767-28-2 441341
4
tannic acid Approved Phase 4 1401-55-4
5
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
6
Amantadine Approved Phase 4 768-94-5 2130
7
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Amisulpride Approved, Investigational Phase 4 71675-85-9, 53583-79-2 2159
10
Galantamine Approved Phase 4 357-70-0 9651
11
Clozapine Approved Phase 4 5786-21-0 2818
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
14
Azathioprine Approved Phase 4 446-86-6 2265
15
Levodopa Approved Phase 4 59-92-7 6047
16
Carbidopa Approved Phase 4 28860-95-9 34359
17
Tetrabenazine Approved, Investigational Phase 4 58-46-8 6018
18
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
19
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
20 Dopamine agonists Phase 4
21 calcium channel blockers Phase 4
22 Serotonin Receptor Agonists Phase 4
23 Serotonin 5-HT2 Receptor Antagonists Phase 4
24 Serotonin 5-HT1 Receptor Agonists Phase 4
25 Nootropic Agents Phase 4
26 Hormones Phase 4
27 Analgesics Phase 4
28 Anti-Infective Agents Phase 4
29 Analgesics, Non-Narcotic Phase 4
30 Antiviral Agents Phase 4
31 Autonomic Agents Phase 4
32 Antiemetics Phase 4
33 Gastrointestinal Agents Phase 4
34 Dopamine Antagonists Phase 4
35 Antiparasitic Agents Phase 4
36 Antimalarials Phase 4
37 Antiprotozoal Agents Phase 4
38 Dopamine D2 Receptor Antagonists Phase 4
39 Antidepressive Agents Phase 4
40 Hormone Antagonists Phase 4
41 Omega 3 Fatty Acid Phase 4
42 Serotonin Uptake Inhibitors Phase 4
43 Antimetabolites Phase 4
44 Cholinesterase Inhibitors Phase 4
45 Paliperidone Palmitate Phase 4
46 GABA Agents Phase 4
47 Anti-Inflammatory Agents Phase 4
48 Anti-Inflammatory Agents, Non-Steroidal Phase 4
49 Chloroquine diphosphate Phase 4 50-63-5
50 Antirheumatic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 251)
# Name Status NCT ID Phase Drugs
1 An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease Unknown status NCT03034538 Phase 4 Zonegran;Zonegran
2 Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study Unknown status NCT00837707 Phase 4 aripiprazole
3 A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study Unknown status NCT02472210 Phase 4 Botulinum Toxin
4 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
5 Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics Completed NCT00888186 Phase 4 levodopa/carbidopa
6 Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study Completed NCT00307450 Phase 4 Levetiracetam
7 A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Completed NCT03698331 Phase 4 Valbenazine;Placebo oral capsule
8 Validation of Dyskinesia Rating Scales Completed NCT01071395 Phase 4 Amantadine;Placebo
9 D-serine Adjuvant Treatment for Parkinson's Disease Completed NCT00215904 Phase 4 D-serine (~2g/day)
10 Tardive Dyskinesia and Cognitive Function Completed NCT00926965 Phase 4 amisulpride;Olanzapine;Conventional antipsychotics
11 A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia Completed NCT00621998 Phase 4 risperidone;olanzapine
12 Treatment of Tardive Dyskinesia With Galantamine Completed NCT00164242 Phase 4 Galantamine
13 Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK. Completed NCT00632762 Phase 4 mantadix
14 Augmentation of Clozapine With Paliperidone in the Treatment of Resistant Schizophrenia Randomized Controlled Study Completed NCT01279213 Phase 4 paliperidone clozapine
15 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
16 Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial Completed NCT02463331 Phase 4 Chloroquine diphosphate;prednisone;azathioprine
17 DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo
18 A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-Eicosapentaenoic Acid (Ethyl-EPA) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia Completed NCT00114595 Phase 4 eicosapentaenoic acid
19 A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Recruiting NCT03891862 Phase 4 Valbenazine;Placebo oral capsule
20 Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response Recruiting NCT03495024 Phase 4 Varenicline
21 Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation Recruiting NCT02480803 Phase 4 Continuous intrajejunal infusion of levodopa-carbidopa
22 The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study) Active, not recruiting NCT00354133 Phase 4 Best Medical Treatment
23 Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study Terminated NCT00477802 Phase 4
24 Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease Unknown status NCT00260793 Phase 3 Ropinirole Hydrochloride
25 Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID) Unknown status NCT02202551 Phase 3 ADS-5102
26 Levetiracetam Treatment of Tardive Dyskinesia Completed NCT00291213 Phase 3 levetiracetam;placebo
27 A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
28 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
29 A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia Completed NCT00105521 Phase 3 Sarizotan;Placebo
30 A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Completed NCT00105508 Phase 3 Sarizotan;Placebo
31 A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02405091 Phase 3 NBI-98854
32 A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects. Completed NCT00363727 Phase 3 ropinirole controlled-release (REQUIP CR) for RLS
33 Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects Completed NCT00360568 Phase 3 Levodopa-carbidopa intestinal gel
34 A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia Completed NCT00672373 Phase 3 Extract of Ginkgo Biloba (EGb-761 capsules);Placebo
35 An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication) Completed NCT02799381 Phase 3 ABT-SLV187;optimized antiparkinsonian treatment
36 Open-Label Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Completed NCT02736955 Phase 3 Valbenazine
37 Double-blind, Placebo-controlled, Randomized, Multicentre Phase II/III Study to Evaluate the Efficacy and Safety of Lisuride, Applied Subcutaneously by Means of a Minipump in Patients With Advanced Parkinson's Disease Refractory to Conventional Oral Therapy Completed NCT00408915 Phase 3 Continuous Subcutaneous Lisuride Infusion
38 Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease Completed NCT00180037 Phase 3 Coenzyme Q10 Nanodispersion (Nanoquinone);Placebo
39 A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy. Completed NCT00199394 Phase 3 Istradefylline (KW-6002)
40 ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study) Completed NCT02274766 Phase 3 ADS-5102
41 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02274558 Phase 3 NBI-98854;Placebo
42 Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) Completed NCT01397422 Phase 2, Phase 3 ADS-5102 (extended release amantadine HCl)
43 Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study) Completed NCT02136914 Phase 3 ADS-5102
44 Deep Brain Stimulation for Parkinson's Disease Trial Completed NCT00053625 Phase 3
45 A 6-Month, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5 - 12 mg/Day) in the Treatment of Adolescents (12 to 17 Years of Age) With Schizophrenia Completed NCT00488319 Phase 3 Paliperidone ER
46 Study of Efficacy and Acceptability of Tetrabenazine in the Late Dyskinetic Syndrome With Neuroleptics: A Randomized, Parallel Group, Double-blind Placebo Controlled Multicentre Trial Completed NCT01543321 Phase 3 Tetrabenazine;Placebo
47 Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study Completed NCT00190008 Phase 3 piracetam
48 Effect of Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Recruiting NCT03790345 Phase 2, Phase 3 Pyridoxine;Cobalamin;Placebo Oral Tablet
49 Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease. Multicenter, International, Placebo-controlled, Randomised, Double Blind Trial Recruiting NCT02617017 Phase 3 Buspirone;Placebo
50 A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents Recruiting NCT03813238 Phase 3 Deutetrabenazine;Placebo

Search NIH Clinical Center for Lingual-Facial-Buccal Dyskinesia

Cochrane evidence based reviews: dyskinesias

Sources

Genetic Tests for Lingual-Facial-Buccal Dyskinesia

About this section

Genetic tests related to Lingual-Facial-Buccal Dyskinesia:

# Genetic test Affiliating Genes
1 Orofacial Dyskinesia 29
Sources

Anatomical Context for Lingual-Facial-Buccal Dyskinesia

About this section

MalaCards organs/tissues related to Lingual-Facial-Buccal Dyskinesia:

40
Brain, Lung, Subthalamic Nucleus, Testes, Heart, Kidney, Liver
Sources

Publications for Lingual-Facial-Buccal Dyskinesia

About this section

Articles related to Lingual-Facial-Buccal Dyskinesia:

(show top 50) (show all 264)
# Title Authors PMID Year
1
Influence of magnesium supplementation and L-type calcium channel blocker on haloperidol-induced movement disturbances. 61
31374223 2019
2
Correction to: Novel mutations in KMT2B offer pathophysiological insights on childhood-onset progressive dystonia. 61
31388109 2019
3
Orofacial Dyskinesia in a Young Man. 61
31545336 2019
4
Novel mutations in KMT2B offer pathophysiological insights into childhood-onset progressive dystonia. 61
31165786 2019
5
18F-FDG PET/CT: an unexpected case of Huntington's disease. 61
31043171 2019
6
Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. 61
30642806 2019
7
Anti-N-methyl-d-aspartate receptor encephalitis during pregnancy: A case report. 61
30788880 2019
8
Clinical Profile and Neuropsychiatric Outcome in Children with Anti-NMDAR Encephalitis. 61
30955001 2019
9
Severe tooth loss secondary to orofacial dyskinesias in anti-NMDA receptor encephalitis. 61
30846455 2019
10
A review for the pharmacological effect of lycopene in central nervous system disorders. 61
30616078 2019
11
Possible nitric oxide mechanism involved in the protective effect of L-theanine on haloperidol-induced orofacial dyskinesia. 61
30942195 2019
12
Infectious Trigger for Autoimmune Encephalitis: A Case Report and Literature Review. 61
31781432 2019
13
TLE1, a key player in neurogenesis, a new candidate gene for autosomal recessive postnatal microcephaly. 61
29758293 2018
14
Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats. 61
28641484 2018
15
Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors. 61
30217539 2018
16
Effect of Biperiden Treatment in Acute Orofacial and Extremity Dyskinesia With Methylphenidate Therapy. 61
28328695 2018
17
L-Theanine Decreases Orofacial Dyskinesia Induced by Reserpine in Rats. 61
29629512 2018
18
Anti-NMDA receptor encephalitis: still unknown and underdiagnosed by physicians and especially by psychiatrists? 61
29050531 2018
19
Dexmethylphenidate Extended Release-Associated Orofacial Dyskinesia in an Adolescent with Autism Spectrum Disorder After Prolonged Use. 61
29781724 2018
20
Acute-onset Orofacial Dyskinesia with a Single Low Dose of Oral Flupentixol: A Case Report. 61
29962578 2018
21
Pediatric NMDAR encephalitis: A single center observation study with a closer look at movement disorders. 61
29396169 2018
22
Protective Effect of L-Theanine on Haloperidol-Induced Orofacial. 61
29374957 2018
23
A review of the outcome of dental implant provision in individuals with movement disorders. 61
30109299 2018
24
Management of Refractory Orofacial Dyskinesia Caused by Anti-N-methyl-d-aspartate Receptor Encephalitis Using Botulinum Toxin. 61
29520252 2018
25
Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. 61
30169182 2017
26
Resveratrol Protects Against Vacuous Chewing Movements Induced by Chronic Treatment with Fluphenazine. 61
28744755 2017
27
An unusual case of refractory status epilepticus in a young lady: anti-NMDA receptor encephalitis. 61
28974594 2017
28
Serial EEG Monitoring in a Patient With Anti-NMDA Receptor Encephalitis. 61
27821481 2017
29
Behavioral and neurochemical effects of alpha lipoic acid associated with omega-3 in tardive dyskinesia induced by chronic haloperidol in rats. 61
28329449 2017
30
[Early Diagnosis of Chorea-Acanthocytosis: Orofacial Dyskinesia, Epileptic Seizures, and HyperCKemia]. 61
28561176 2017
31
Influence of magnesium supplementation on movement side effects related to typical antipsychotic treatment in rats. 61
27816557 2017
32
Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy. 61
28835863 2017
33
Brain Calcification and Movement Disorders. 61
28097511 2017
34
Methylmalonic Acidemia with Novel MUT Gene Mutations. 61
29158924 2017
35
Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation. 61
27823630 2016
36
NMDA-receptor associated encephalitis in a woman with mature cystic ovarian teratoma. 61
29733562 2016
37
Crocin prevents haloperidol-induced orofacial dyskinesia: possible an antioxidant mechanism. 61
27872703 2016
38
Anti-collapsin response mediator protein 5 encephalitis masquerading as a low-grade brain tumour. 61
27247429 2016
39
Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors. 61
27306571 2016
40
Plasmodium falciparum and Mycoplasma pneumoniae co-infection presenting with cerebral malaria manifesting orofacial dyskinesia and haemophagocytic lymphohistiocytosis. 61
27609213 2016
41
Clinical variability of neuroacanthocytosis syndromes-a series of six patients with long follow-up. 61
27310290 2016
42
Harpagophytum Procumbens Ethyl Acetate Fraction Reduces Fluphenazine-Induced Vacuous Chewing Movements and Oxidative Stress in Rat Brain. 61
26732278 2016
43
Non-Wilsonian hepatolenticular degeneration: Clinical and MRI observations in four families from south India. 61
26765764 2016
44
Diminution of falsely elevated tumour markers following immunosuppression for systemic lupus erythematosus with neurological involvement. 61
27048397 2016
45
Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation. 61
26712377 2016
46
Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat. 61
24464858 2015
47
Orofacial Dyskinesia in Elderly. 61
30838247 2015
48
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1. 61
26348804 2015
49
Magnesium Supplementation Prevents and Reverses Experimentally Induced Movement Disturbances in Rats: Biochemical and Behavioral Parameters. 61
25686766 2015
50
Management of Edentulous Orofacial Dyskinesia. 61
26329418 2015
Sources

Variations for Lingual-Facial-Buccal Dyskinesia

About this section

ClinVar genetic disease variations for Lingual-Facial-Buccal Dyskinesia:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CSTB NM_000100.3(CSTB):c.202C>T (p.Arg68Ter)SNV Pathogenic 8396 rs74315442 21:45194178-45194178 21:43774297-43774297
2 46;XX;t(2;14)(q21;q24.3)dnTranslocation Uncertain significance 267947
3 HERC2 NM_004667.5(HERC2):c.5045A>G (p.Asn1682Ser)SNV Uncertain significance 599009 rs140073033 15:28474681-28474681 15:28229535-28229535
4 RYR1 NM_000540.2(RYR1):c.1312G>C (p.Glu438Gln)SNV Uncertain significance 599010 rs765668209 19:38943526-38943526 19:38452886-38452886
Sources

Expression for Lingual-Facial-Buccal Dyskinesia

About this section
Search GEO for disease gene expression data for Lingual-Facial-Buccal Dyskinesia.
Sources

Pathways for Lingual-Facial-Buccal Dyskinesia

About this section

Pathways related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 65
Show member pathways
 13.34 XK KEL HTR2C GRIN1 DRD5 DRD4
2
Beta-Adrenergic Signaling 63
Show member pathways
 12.59 DRD5 DRD4 DRD3 DRD2 DRD1
3
Circadian entrainment 36
Show member pathways
 12.51 GRIN1 DRD5 DRD4 DRD3 DRD2 DRD1
4
cAMP signaling pathway 36
12.11 GRIN1 DRD5 DRD2 DRD1
5
Dopamine-DARPP32 Feedback onto cAMP Pathway 63
12.09 GRIN1 DRD5 DRD4 DRD3 DRD2 DRD1
7
Calcium signaling pathway 36
Show member pathways
 12.03 HTR2C GRIN1 DRD5 DRD1
8
Long-term potentiation 36
Show member pathways
 11.94 GRIN1 DRD5 DRD4 DRD2 DRD1
9
Amphetamine addiction 36
Show member pathways
 11.78 GRIN1 DRD2 DRD1
10
Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics 60
Show member pathways
 11.71 DRD4 DRD3 DRD2
11
Gap junction 36
11.63 HTR2C DRD2 DRD1
12
Monoamine GPCRs 1
Show member pathways
 11.47 HTR2C DRD5 DRD4 DRD3 DRD2 DRD1
13
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.85 HTR2C DRD2
14
DARPP-32 Phosphorylation 64
10.8 DRD5 DRD3 DRD2 DRD1
15
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.38 DRD5 DRD4 DRD3 DRD2 DRD1
Sources

GO Terms for Lingual-Facial-Buccal Dyskinesia

About this section

Cellular components related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 HTR2C GRIN1 DRD5 DRD4 DRD3 DRD2
2 dendrite GO:0030425 9.72 HTR2C GRIN1 DRD4 DRD2 DRD1
3 dendritic spine GO:0043197 9.65 GRIN1 DRD2 DRD1
4 GABA-ergic synapse GO:0098982 9.58 DRD3 DRD2 DRD1
5 synaptic cleft GO:0043083 9.46 LGI1 GRIN1
6 dopaminergic synapse GO:0098691 9.43 DRD3 DRD2
7 ciliary membrane GO:0060170 9.43 DRD5 DRD2 DRD1
8 glutamatergic synapse GO:0098978 9.43 LGI1 GRIN1 DRD4 DRD3 DRD2 DRD1
9 non-motile cilium GO:0097730 9.33 DRD5 DRD2 DRD1
10 cell GO:0005623 9.32 XK VPS13A KEL HTR2C GRIN1 DRD5

Biological processes related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.27 HTR2C FGF14 DRD5 DRD4 DRD3 DRD2
2 G protein-coupled receptor signaling pathway GO:0007186 10.19 HTR2C DRD5 DRD4 DRD3 DRD2 DRD1
3 response to drug GO:0042493 10 HTR2C DRD3 DRD2 DRD1
4 autophagy GO:0006914 9.91 VPS13A DRD3 DRD2
5 response to ethanol GO:0045471 9.89 GRIN1 DRD3 DRD2
6 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.89 DRD5 DRD3 DRD2 DRD1
7 locomotory behavior GO:0007626 9.89 VPS13A HTR2C DRD3 DRD2 DRD1
8 social behavior GO:0035176 9.87 VPS13A GRIN1 DRD4 DRD3
9 learning GO:0007612 9.86 GRIN1 DRD3 DRD1
10 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.86 HTR2C DRD4 DRD1
11 visual learning GO:0008542 9.86 GRIN1 DRD3 DRD2 DRD1
12 response to cocaine GO:0042220 9.85 DRD5 DRD3 DRD2 DRD1
13 adult locomotory behavior GO:0008344 9.84 GRIN1 DRD4 CSTB
14 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.84 HTR2C DRD3 DRD2 DRD1
15 feeding behavior GO:0007631 9.82 HTR2C DRD2 DRD1
16 behavioral fear response GO:0001662 9.81 HTR2C DRD4 DRD1
17 response to morphine GO:0043278 9.81 GRIN1 DRD3 DRD2
18 associative learning GO:0008306 9.81 GRIN1 DRD5 DRD2 DRD1
19 negative regulation of blood pressure GO:0045776 9.8 DRD5 DRD3 DRD2
20 arachidonic acid secretion GO:0050482 9.79 DRD4 DRD3 DRD2
21 negative regulation of protein secretion GO:0050709 9.79 DRD4 DRD3 DRD2
22 negative regulation of voltage-gated calcium channel activity GO:1901386 9.78 DRD4 DRD3 DRD2
23 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.78 DRD5 DRD3 DRD2 DRD1
24 behavioral response to ethanol GO:0048149 9.77 DRD4 DRD3 DRD2
25 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.76 DRD5 DRD3 DRD1
26 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.75 DRD4 DRD3 DRD2
27 skeletal muscle fiber development GO:0048741 9.74 XK KEL
28 negative regulation of adenylate cyclase activity GO:0007194 9.73 DRD3 DRD2
29 regulation of cell size GO:0008361 9.73 XK KEL
30 regulation of long-term neuronal synaptic plasticity GO:0048169 9.73 GRIN1 DRD2
31 temperature homeostasis GO:0001659 9.73 DRD2 DRD1
32 negative regulation of cytosolic calcium ion concentration GO:0051481 9.73 DRD3 DRD2
33 dopamine receptor signaling pathway GO:0007212 9.73 DRD4 DRD3 DRD2 DRD1
34 transmission of nerve impulse GO:0019226 9.72 DRD5 DRD1
35 long-term synaptic depression GO:0060292 9.72 DRD5 DRD1
36 startle response GO:0001964 9.72 GRIN1 DRD2
37 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.71 DRD3 DRD2
38 positive regulation of renal sodium excretion GO:0035815 9.71 DRD3 DRD2
39 grooming behavior GO:0007625 9.71 DRD2 DRD1
40 G protein-coupled receptor internalization GO:0002031 9.71 DRD3 DRD2
41 striatum development GO:0021756 9.71 DRD2 DRD1
42 behavioral response to cocaine GO:0048148 9.71 DRD4 DRD3 DRD2 DRD1
43 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.7 DRD4 DRD3
44 regulation of potassium ion transport GO:0043266 9.7 DRD3 DRD2
45 regulation of dopamine metabolic process GO:0042053 9.7 DRD4 DRD1
46 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.7 DRD3 DRD2 DRD1
47 peristalsis GO:0030432 9.69 DRD2 DRD1
48 mating behavior GO:0007617 9.69 DRD5 DRD1
49 cellular response to catecholamine stimulus GO:0071870 9.68 DRD5 DRD1
50 cerebral cortex GABAergic interneuron migration GO:0021853 9.68 DRD2 DRD1

Molecular functions related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.88 HTR2C DRD5 DRD4 DRD3 DRD2 DRD1
2 drug binding GO:0008144 9.62 HTR2C DRD4 DRD3 DRD2
3 adrenergic receptor activity GO:0004935 9.46 DRD5 DRD3 DRD2 DRD1
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD4 DRD3 DRD2
5 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.37 DRD5 DRD1
6 dopamine binding GO:0035240 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
7 dopamine neurotransmitter receptor activity GO:0004952 9.02 DRD5 DRD4 DRD3 DRD2 DRD1
Sources

Sources for Lingual-Facial-Buccal Dyskinesia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....